Abiopharma

New Form SCHEDULE 13G - Sintx Technologies, Inc. Filed: 2025-09-03 AccNo: 0001641172-25-026307 Size: 7 KB

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XORTX Initiates IND Preparation for XORLO™ in Gout Program

Sono-Tek Wins Order for Medical Device Coating Systems Valued at Over $5 Million

Precigen Announces Up to $125 Million Non-Dilutive Financing

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

SINTX Technologies Publishes Landmark Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

TScan Therapeutics to Participate in Upcoming Investor Conferences

Breckenridge Distillery Expands California Distribution with Winebow

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting